Review
Open access
Oct 2026
Unraveling Vulnerabilities and Pathways Responsible for AITL Malignancy to Improve Patients’ Treatment
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma characterized by poor clinical outcomes following conventional CHOP-based chemotherapy and the lack of effective disease-specific therapeutic options. The disease finds its origin in CD4 follicular helper T (Tfh) cells and...
C. Martinello, Adrien Krug, Pau Marin-Escudero et al.
· Pharmaceutics · 0 citations